A Rare but Fascinating Disorder: Case Collection of Patients with Schnitzler Syndrome

Background. Schnitzler syndrome is a rare disorder characterized by a chronic urticarial rash and monoclonal gammopathy (IgM in more than 90% of the cases). It is difficult to distinguish from other neutrophilic urticarial dermatoses, and diagnosis is based on the Strasbourg criteria. Interleukin-1...

Full description

Saved in:
Bibliographic Details
Main Authors: Maaman Bashir, Brittany Bettendorf, Richard Hariman
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Case Reports in Rheumatology
Online Access:http://dx.doi.org/10.1155/2018/7041576
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832550172066840576
author Maaman Bashir
Brittany Bettendorf
Richard Hariman
author_facet Maaman Bashir
Brittany Bettendorf
Richard Hariman
author_sort Maaman Bashir
collection DOAJ
description Background. Schnitzler syndrome is a rare disorder characterized by a chronic urticarial rash and monoclonal gammopathy (IgM in more than 90% of the cases). It is difficult to distinguish from other neutrophilic urticarial dermatoses, and diagnosis is based on the Strasbourg criteria. Interleukin-1 is considered the key mediator, and interleukin-1 inhibitors are considered first line treatment. Here, we present two cases of Schnitzler syndrome, both successfully treated with anakinra. Objectives. To increase awareness regarding clinical presentation, diagnosis, and treatment of this rare disorder. Cases. We describe the clinical features and disease course of two patients with Schnitzler syndrome, diagnosed using the Strasbourg criteria. Both were treated with anakinra with remarkable response to therapy. Conclusion. Schnitzler syndrome is a rare and underdiagnosed disorder. High suspicion should be maintained in patients with chronic urticaria-like dermatoses, intermittent fevers, and arthralgias. A serum protein electrophoresis and immunofixation should be performed in these patients. The diagnosis is important to recognize as Schnitzler syndrome is associated with malignancy. A lymphoproliferative disorder develops in about 20% of patients at an average of 7.6 years after onset of symptoms. Thus, patients warrant long-term follow-up. IL-1 inhibitors are extremely effective in relieving symptoms and are considered first line therapy.
format Article
id doaj-art-db8c2f9a27d84ee18c80458bae09be92
institution Kabale University
issn 2090-6889
2090-6897
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series Case Reports in Rheumatology
spelling doaj-art-db8c2f9a27d84ee18c80458bae09be922025-02-03T06:07:30ZengWileyCase Reports in Rheumatology2090-68892090-68972018-01-01201810.1155/2018/70415767041576A Rare but Fascinating Disorder: Case Collection of Patients with Schnitzler SyndromeMaaman Bashir0Brittany Bettendorf1Richard Hariman2Division of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USADivision of Rheumatology, Department of Medicine, University of Iowa, Iowa City, IA 52242, USADivision of Rheumatology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USABackground. Schnitzler syndrome is a rare disorder characterized by a chronic urticarial rash and monoclonal gammopathy (IgM in more than 90% of the cases). It is difficult to distinguish from other neutrophilic urticarial dermatoses, and diagnosis is based on the Strasbourg criteria. Interleukin-1 is considered the key mediator, and interleukin-1 inhibitors are considered first line treatment. Here, we present two cases of Schnitzler syndrome, both successfully treated with anakinra. Objectives. To increase awareness regarding clinical presentation, diagnosis, and treatment of this rare disorder. Cases. We describe the clinical features and disease course of two patients with Schnitzler syndrome, diagnosed using the Strasbourg criteria. Both were treated with anakinra with remarkable response to therapy. Conclusion. Schnitzler syndrome is a rare and underdiagnosed disorder. High suspicion should be maintained in patients with chronic urticaria-like dermatoses, intermittent fevers, and arthralgias. A serum protein electrophoresis and immunofixation should be performed in these patients. The diagnosis is important to recognize as Schnitzler syndrome is associated with malignancy. A lymphoproliferative disorder develops in about 20% of patients at an average of 7.6 years after onset of symptoms. Thus, patients warrant long-term follow-up. IL-1 inhibitors are extremely effective in relieving symptoms and are considered first line therapy.http://dx.doi.org/10.1155/2018/7041576
spellingShingle Maaman Bashir
Brittany Bettendorf
Richard Hariman
A Rare but Fascinating Disorder: Case Collection of Patients with Schnitzler Syndrome
Case Reports in Rheumatology
title A Rare but Fascinating Disorder: Case Collection of Patients with Schnitzler Syndrome
title_full A Rare but Fascinating Disorder: Case Collection of Patients with Schnitzler Syndrome
title_fullStr A Rare but Fascinating Disorder: Case Collection of Patients with Schnitzler Syndrome
title_full_unstemmed A Rare but Fascinating Disorder: Case Collection of Patients with Schnitzler Syndrome
title_short A Rare but Fascinating Disorder: Case Collection of Patients with Schnitzler Syndrome
title_sort rare but fascinating disorder case collection of patients with schnitzler syndrome
url http://dx.doi.org/10.1155/2018/7041576
work_keys_str_mv AT maamanbashir ararebutfascinatingdisordercasecollectionofpatientswithschnitzlersyndrome
AT brittanybettendorf ararebutfascinatingdisordercasecollectionofpatientswithschnitzlersyndrome
AT richardhariman ararebutfascinatingdisordercasecollectionofpatientswithschnitzlersyndrome
AT maamanbashir rarebutfascinatingdisordercasecollectionofpatientswithschnitzlersyndrome
AT brittanybettendorf rarebutfascinatingdisordercasecollectionofpatientswithschnitzlersyndrome
AT richardhariman rarebutfascinatingdisordercasecollectionofpatientswithschnitzlersyndrome